Atlanta Braves star Jurickson Profar has been handed a devastating blow, with reports confirming he will miss the entire 2026 Major League Baseball season. This follows the denial of his appeal against a positive test for performance-enhancing drugs, resulting in a severe 162-game suspension.
A Second Offense Leads to Full-Season Ban
Profar, aged 33, now faces this lengthy ban after testing positive for prohibited substances for the second time in his career. The suspension means he will forfeit his entire $15 million salary for the 2026 season, a significant financial penalty on top of the competitive setback.
ESPN's Jeff Passan broke the news on Wednesday, also confirming that Profar will be ineligible for any postseason play in 2026, further compounding the impact on both the player and his team.
History of PED Violations
This is not Profar's first encounter with MLB's drug policy. Last year, he was suspended for 80 games without pay after testing positive for Chorionic Gonadotrophin (hCG). The latest violation triggers MLB's enhanced penalties for repeat offenders, which were increased to a full season in 2024.
With this ruling, Profar becomes just the sixth player in MLB history to receive a 162-game suspension for performance-enhancing drug use, placing him among a small group of athletes facing the league's toughest sanctions.
Profar's Career and Recent Performance
Profar's career has been marked by both promise and challenges. Once baseball's top prospect, he debuted at just 19 with the Texas Rangers but faced numerous injury setbacks throughout his early years.
Despite these obstacles, he achieved All-Star status with the San Diego Padres in 2024. Shortly after, in January 2025, he signed a lucrative $42 million contract with the Atlanta Braves, just two months before receiving his first suspension.
After serving his initial ban last year, Profar returned to the Braves in July, making a notable impact. He posted a batting line of .245/.353/.434 with 14 home runs, demonstrating his value to the team's offensive lineup.
Team Reaction and Future Plans
Following his first suspension, Profar expressed remorse, stating, 'It is because of my deep love and respect for this game that I would never knowingly do anything to cheat it.' The Braves organization responded with disappointment but support, saying they were 'surprised and extremely disappointed' while affirming their backing of MLB's drug program and hoping Profar would learn from the experience.
The Braves now face significant roster challenges. Profar's absence is particularly damaging as the team already deals with injuries to starting pitchers Spencer Schwellenbach and Hurston Waldrep, both sidelined with elbow issues.
Manager Walt Weiss must now overhaul his 2026 strategy. Profar was expected to shift to designated hitter and occupy a key spot in the batting order after undergoing sports hernia surgery during the offseason. His suspension forces a complete reevaluation of the team's offensive and defensive arrangements for the upcoming campaign.
Looking Ahead to 2027
When Profar eventually returns for the 2027 season, he will have one year remaining on his contract with the Braves, set to earn another $15 million. This future opportunity provides a slim silver lining, but the immediate consequences of his suspension will undoubtedly reshape both his career trajectory and the Braves' competitive prospects for 2026.
The case highlights MLB's ongoing efforts to maintain integrity in the sport through stringent anti-doping measures, while also showcasing the personal and professional ramifications for players who violate these policies.
